Advocacy groups and trade associations are blanketing the Hill to elevate their priorities in the looming tax fight.

Handelsbanken Fonder AB reduced its stake in Vertex Pharmaceuticals by 28.1% in Q4, selling 115,479 shares. The fund now owns ...

The additive manufacturing sector continues to show near-limitless potential. Innovations have taken 3D printers from creating customized figurines all the way to printing entire neighborhoods, ...

RAD Security, a San Francisco-based provider of security for cloud-focused infrastructure, raised $14 million in Series A ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

The U.S. FDA approved 12 drugs in January, falling below the 2024 monthly average of 19. Only three new molecular entities received approval, trailing the yearly average of just over four per month.

Shares of Vertex Pharmaceuticals Inc. VRTX rallied 1.82% to $480.33 Thursday, on what proved to be an all-around grim trading ...

The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.

A newly approved pain medication, suzetrigine, is the first nonopioid analgesic in 25 years to receive clearance from the U.S ...

Biotechnology company Vertex Pharmaceuticals (VRTX) reported mixed results for the fourth quarter of 2024. While revenue surpassed analyst expectations, driven by strong demand for its cystic ...